Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.14365
Abstract: Selexipag is a prostacyclin receptor agonist approved for the treatment of pulmonary arterial hypertension. Cytochrome P450 (CYP) 2C8 is involved in the metabolism of selexipag and its active metabolite, ACT‐333679. This study evaluated the interaction… read more here.
Keywords: selexipag; active metabolite; cyp2c8 inhibitor; clopidogrel cyp2c8 ... See more keywords